Clinical trials: Low Risk Prostate Cancer, active
Prostate Cancer, Localized Prostate Carcinoma
Erectile Function PRESERVation in Definitive Radiotherapy for Prostate Cancer by MRI-Enhanced Adaptive Sparing of the Neurovascular Bundle
Radiotherapy is a standard and highly effective treatment for prostate cancer that is confined to the prostate gland. One modern approach, called stereotactic body radiotherapy (SBRT), delivers treatment in just five sessions and…
- Conditions
- Prostate Cancer, Localized Prostate Carcinoma, Low-Risk Prostate Cancer, Intermediate-risk Prostate Cancer
- Trial name
- EF-PRESERVE (NCT07916779)
- Testing
- Daily Adaptive MR-Enhanced SBRT with Neurovascular Bundle Sparing
- Where
- Switzerland
- Volunteers
- 48 people
- Sponsor
- University of Zurich
Prostate Cancer
Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer
This study will offer men with intermediate risk prostate cancer who are suitable for, and interested in, prostate brachytherapy, the opportunity to be randomized between low dose rate (LDR) brachytherapy using permanent…
- Trial name
- NCT02692105
- Testing
- Low dose rate prostate brachytherapy, High Dose Rate prostate brachytherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR Brachytherapy
Optimal non surgical treatment of prostate cancer requires dose escalation which is frequently provided by adding a brachytherapy "boost" to a short course of external beam radiotherapy.
- Trial name
- BrachyQOL (NCT01936883)
- Testing
- HDR, LDR
- Where
- Canada
- Volunteers
- 195 people
- Sponsor
- British Columbia Cancer Agency
Prostate Cancer
Stereotactic Ablative Radiation Therapy for Prostate Cancer
This single arm trial will investigate a novel way to plan and deliver SABR for prostate cancer. Prostate-directed SABR will be high-dose SABR (40 Gy in 5 fractions) with central sparing of the urethra and peripheral sparing of…
- Trial name
- SUPR-SABR (NCT05668351)
- Testing
- SUPR-SABR treatment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Medical University of South Carolina
Low-to-intermediate-risk Prostate Carcinoma
Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy With SPACEOAR TM for Patients With Low-to-intermediate Risk Localized Prostate Cancer (DESAR-L)
A single institution with a single group, a phase II study, low- and medium-risk studies performed after biodegradable substance injection prostate cancer dosage increase.
- Trial name
- DESAR-L (NCT06461819)
- Testing
- Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Prostate Carcinoma, Stage I Prostate Cancer AJCC v8
MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer
This clinical trial tests whether the magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) procedure is safe and effective in treating patients with low to intermediate grade prostate cancer.
- Conditions
- Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT05438563
- Testing
- MRI-Guided Transurethral Ultrasound Ablation, Questionnaire Administration, Digital Rectal Examination
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Prostate Cancer
A Trial Evaluating Toxicity of SBRT and LDRB in Localized Prostate Cancer.
The goal of this clinical trial is to compare SBRT (Stereotactic Body RadioTherapy) to LDRB (Low-Dose Rate Brachytherapy with Iodine-125 seed implant) in patients with low and favourable intermediate-risk prostate cancer.
- Trial name
- NCT06052683
- Testing
- Low-Dose Rate Brachytherapy to the prostate using Iodine-125 seed implant, Stereotactic Body Radiation Therapy to the prostate
- Where
- Canada
- Volunteers
- 208 people
- Sponsor
- CHU de Quebec-Universite Laval
Advanced Prostate Cancer, Metastatic Prostate Cancer
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low…
- Conditions
- Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
- Trial name
- NCT06062745
- Testing
- 18F-fluciclovine, PET/CT
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Brigham and Women's Hospital
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Low-volume Metastasis
A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer
This is an observational study in which medical records of Japanese men with low-volume metastatic hormone-sensitive prostate cancer (mHSPC), who received treatment with a combination therapy of darolutamide with an androgen…
- Trial name
- HAYATE (NCT06661122)
- Testing
- Darolutamide (BAY1841788) + docetaxel + ADT
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Bayer
Low Risk Prostate Cancer
Decision Making in Men With Early Stage Prostate Cancer Patients and Partners/Close Allies
The purpose of this study is to collect information on how patients and their partners/close allies make treatment decisions when they have been diagnosed with early stage prostate cancer.
- Trial name
- NCT01877070
- Testing
- assessments
- Where
- 3 sites in United States
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostatic Neoplasms, Low Grade Prostate Cancer
Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression
The purpose of this study is to determine whether marine omega-3 fatty acids and 5-alpha-reductase inhibitor are effective in the progression of prostate cancer for low-risk prostate cancer patients.
- Trial name
- NCT01653925
- Testing
- Dietary intervention first, Drug (Dutasteride) intervention first
- Where
- 2 sites in Canada
- Volunteers
- 120 people
- Sponsor
- CHU de Quebec-Universite Laval
Prostate Cancer, Cancer of the Prostate
Low-Count Quantitative SPECT for Men Treated With Radium-223
Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased cells while sparing adjacent normal tissues.
- Trial name
- NCT07221825
- Testing
- Low-count quantitative single-photon emission computed tomography imaging
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Washington University School of Medicine
Prostate Cancer
A Prospective, Single-Arm, Pilot Study of the ALPFA BPH PFA System in Men With Low, Intermediate and High-Risk Prostate Cancer
The primary objective of this study is to evaluate the safety and effectiveness of PFA in patients with localized prostate cancer.
- Trial name
- NCT07492381
- Testing
- ALPFA BPH PFA System
- Volunteers
- 50 people
- Sponsor
- ALPFA Medical
Prostate Cancer
Robotic Hemi-Prostatectomy With Urethral Preservation in Low and Intermediate Risk Monolateral Prostate Cancer
On the basis of the now consolidated literature and clinical experience of focal therapies, the execution of partial prostatectomy/hemiprostatectomy with robot-assisted laparoscopic technique can be proposed in a well-selected…
- Trial name
- RETURN (NCT05832736)
- Testing
- Robotic hemi-prostatectomy with urethral preservation
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Prostate Cancer
Validation Study on the Impact of Decipher® Testing - VANDAAM Study
The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same accuracy in African-American men (AAM) as…
- Trial name
- VANDAAM (NCT02723734)
- Testing
- Decipher® Testing
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer Patients Treated by Radiotherapy
Two-fraction Proton Therapy With MRI Guidance for Prostate Cancer: A Phase II Trial
This study is testing a shorter treatment method for prostate cancer using proton therapy (PT), which is very precise and may cause fewer side effects compared to traditional radiation.
- Trial name
- PT2 (NCT07130682)
- Testing
- Pencil Beam Proton Therapy Treatment Machine
- Where
- Hong Kong
- Volunteers
- 35 people
- Sponsor
- Hong Kong Sanatorium & Hospital
Prostate Cancer
Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)
The aim of this prospective, single-arm phase II study is the individualization of both radiotherapy (RT) and androgen deprivation therapy (ADT) duration for patients with high-risk localized prostate cancer (PCa) according to…
- Trial name
- HypoPro (NCT06772441)
- Testing
- Androgen deprivation therapy (ADT)
- Where
- Cyprus
- Volunteers
- 30 people
- Sponsor
- German Oncology Center, Cyprus
PROSTATE CANCER
Two-fraction Versus Five-fraction Stereotactic Radiotherapy for Localized Prostate Cancer
The goal of this clinical trial is to compare two dose schedules of stereotactic radiation therapy in patients with localized prostate cancer.
- Trial name
- SABR-Dual (NCT06027892)
- Testing
- Two-fraction stereotactic radiotherapy, Five-fraction stereotactic radiotherapy
- Where
- Israel
- Volunteers
- 562 people
- Sponsor
- Rabin Medical Center
Prostate Cancer
Two Fraction Prostate SBRT With DIL SIB
Phase I/Ib, single arm trial of Two-Fraction Stereotactic Body Radiation Therapy (SBRT) with an MRI directed, dominant intraprostatic lesion (DIL), simultaneous integrated boost (SIB) based on genomic classification in the…
- Trial name
- NCT05864196
- Testing
- Two-Fraction Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- NYU Langone Health
Metastatic Prostate Cancer
Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)
The study is being done to see if a small daily dose of naltrexone (LDN, 3 mg pill) can help reduce tiredness (fatigue) in men with prostate cancer.
- Trial name
- NCT07224009
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Arkansas